A chemical screen identifies PRMT5 as a therapeutic vulnerability for paclitaxel-resistant triple-negative breast cancer

Kejing Zhang, Juan Wei, She-Yu Zhang, Liyan Fei, Lu Guo, Xueying Liu, YiShuai Ji, Wenjun Chen, Felipe E. Ciamponi, Weichang Chen, MengXi Li, Jie Zhai, Ting Fu, Katlin B. Massirer, Yang Yu, Mathieu Lupien, Yong Wei, C.H. Arrowsmith, Qin Wu, Weihong Tan